CA
NZ
UK
US
AU
IND
Last update at 2025-07-03T19:30:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Was Jim Cramer Right About Danaher Corporation (DHR)?
Thu 22 May 25, 08:40 PMWhy Is Danaher (DHR) Down 4.8% Since Last Earnings Report?
Thu 22 May 25, 03:30 PMHere's Why Investors Should Consider Retaining Danaher Stock Now
Thu 22 May 25, 01:54 PMDanaher, Illumina, Globalstar, and Insperity Shares Plummet, What You Need To Know
Wed 21 May 25, 08:09 PMLee Ainslie's Strategic Moves: A Deep Dive into Kenvue Inc's 3.59% Portfolio Impact
Thu 15 May 25, 11:22 PMDaniel Loeb's Strategic Moves: Danaher Corp Exit Impacts Portfolio by -5.87%
Thu 15 May 25, 11:15 PMQ1 Research Tools & Consumables Earnings: Danaher (NYSE:DHR) Impresses
Thu 15 May 25, 03:35 AMDanaher Corporation (DHR): Among Billionaire Lei Zhang’s Stock Picks with Huge Upside Potential
Fri 09 May 25, 09:25 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 8292.00M | 7598.00M | 4495.00M | 3305.30M | 3292.80M |
| Minority interest | - | - | 11.00M | 11.30M | 12.30M |
| Net income | 7209.00M | 6433.00M | 3646.00M | 3008.20M | 2650.90M |
| Selling general administrative | 8516.00M | 8198.00M | 6896.00M | 5588.30M | 6472.10M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 18949.00M | 17952.00M | 12475.00M | 9983.70M | 11107.10M |
| Reconciled depreciation | 2222.00M | 2168.00M | 1775.00M | 1189.50M | 1307.70M |
| Ebit | 8688.00M | 7465.00M | 4231.00M | 3269.40M | 3450.20M |
| Ebitda | 10725.00M | 10100.00M | 6116.00M | 4609.90M | 4757.90M |
| Depreciation and amortization | 2037.00M | 2635.00M | 1885.00M | 1340.50M | 1307.70M |
| Non operating income net other | -185.00000M | 371.00M | 539.00M | 144.50M | 46.40M |
| Operating income | 8688.00M | 7465.00M | 4231.00M | 3269.40M | 3403.80M |
| Other operating expenses | 22783.00M | 21988.00M | 18053.00M | 14641.70M | 16489.20M |
| Interest expense | 211.00M | 238.00M | 275.00M | 108.60M | 157.40M |
| Tax provision | 1083.00M | 1251.00M | 849.00M | 873.00M | 641.90M |
| Interest income | 170.00M | 227.00M | 204.00M | 139.00M | 9.20M |
| Net interest income | -170.00000M | -227.00000M | -204.00000M | 30.40M | -148.20000M |
| Extraordinary items | 0.00000M | 86.00M | 0.00000M | 575.90M | 251.60M |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 1083.00M | 1251.00M | 849.00M | 873.00M | 641.90M |
| Total revenue | 31471.00M | 29453.00M | 22284.00M | 17911.10M | 19893.00M |
| Total operating expenses | 10261.00M | 10487.00M | 8244.00M | 6714.30M | 7703.30M |
| Cost of revenue | 12522.00M | 11501.00M | 9809.00M | 7927.40M | 8785.90M |
| Total other income expense net | -396.00000M | 133.00M | 264.00M | 35.90M | 37.20M |
| Discontinued operations | - | 86.00M | 86.00M | 575.90M | 244.60M |
| Net income from continuing ops | 7209.00M | 6347.00M | 3646.00M | 2432.30M | 2650.90M |
| Net income applicable to common shares | 7103.00M | 6269.00M | 3510.00M | 2939.80M | 2650.90M |
| Preferred stock and other adjustments | 106.00M | 164.00M | 136.00M | 68.40M | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 84350.00M | 83184.00M | 76161.00M | 62081.60M | 47832.50M |
| Intangible assets | 20300.00M | 22843.00M | 21282.00M | 9749.70M | 11673.10M |
| Earning assets | - | - | - | - | - |
| Other current assets | 1860.00M | 1664.00M | 1430.00M | 864.60M | 906.30M |
| Total liab | 34260.00M | 38007.00M | 36384.00M | 31799.70M | 19605.80M |
| Total stockholder equity | 50082.00M | 45167.00M | 39766.00M | 30270.60M | 28214.40M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 3854.00M | 3950.00M | 4130.00M | 2517.50M | 2391.70M |
| Common stock | 9.00M | 9.00M | 9.00M | 8.40M | 8.20M |
| Capital stock | 1677.00M | 3277.00M | 3277.00M | 1608.00M | 8.20M |
| Retained earnings | 39205.00M | 32827.00M | 27159.00M | 24166.30M | 25163.00M |
| Other liab | 5922.00M | 7699.00M | 7789.00M | 4711.80M | 5075.80M |
| Good will | 39752.00M | 41184.00M | 35420.00M | 22712.50M | 25906.00M |
| Other assets | 4459.00M | 3719.00M | 2395.00M | 923.40M | 5587.50M |
| Cash | 5995.00M | 2586.00M | 6035.00M | 19912.30M | 787.80M |
| Cash and equivalents | 5995.00M | 2586.00M | 6035.00M | 19912.30M | 787.80M |
| Total current liabilities | 8389.00M | 8140.00M | 7402.00M | 4932.10M | 4841.50M |
| Current deferred revenue | 1648.00M | 1613.00M | 1212.00M | 687.80M | 685.20M |
| Net debt | 13682.00M | 19590.00M | 15169.00M | 1816.80M | 8952.50M |
| Short term debt | 591.00M | 8.00M | 11.00M | 212.40M | 51.80M |
| Short long term debt | 591.00M | 8.00M | 11.00M | 212.40M | 51.80M |
| Short long term debt total | 19677.00M | 22176.00M | 21204.00M | 21729.10M | 9740.30M |
| Other stockholder equity | 12072.00M | 10090.00M | 9698.00M | 7564.60M | 5834.30M |
| Property plant equipment | 3956.00M | 3790.00M | 3262.00M | 2302.00M | 2511.20M |
| Total current assets | 15883.00M | 11648.00M | 13802.00M | 25596.60M | 7093.80M |
| Long term investments | - | - | - | 33.70M | 38.30M |
| Net tangible assets | -11638.00000M | -22128.00000M | -20204.00000M | -3791.20000M | -9364.70000M |
| Short term investments | - | - | - | - | - |
| Net receivables | 4918.00M | 4631.00M | 4045.00M | 3191.40M | 3489.60M |
| Long term debt | 19086.00M | 22168.00M | 21193.00M | 21516.70M | 9688.50M |
| Inventory | 3110.00M | 2767.00M | 2292.00M | 1628.30M | 1910.10M |
| Accounts payable | 2296.00M | 2569.00M | 2049.00M | 1514.40M | 1712.80M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | 8.00M | 10.00M | 11.00M | 11.30M | 12.30M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -2872.00000M | -1027.00000M | -368.00000M | -3068.30000M | -2791.10000M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | 9.00M | 9.00M | 9.00M | 8.40M | 8.20M |
| Preferred stock total equity | 1668.00M | 3268.00M | 3268.00M | 1599.60M | - |
| Retained earnings total equity | 39205.00M | 32827.00M | 27159.00M | 24166.30M | 25163.00M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 4459.00M | 3719.00M | 2395.00M | 1720.80M | 648.40M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 68467.00M | 71536.00M | 62359.00M | 36485.00M | 40738.70M |
| Capital lease obligations | 1062.00M | 1096.00M | 974.00M | 796.90M | - |
| Long term debt total | 19086.00M | 22168.00M | 21193.00M | 21516.70M | 9688.50M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -2234.00000M | -808.00000M | -329.00000M | -241.00000M | -126.70000M |
| Change to liabilities | 81.00M | 320.00M | 372.00M | 422.60M | 216.90M |
| Total cashflows from investing activities | -2234.00000M | -12987.00000M | -21239.00000M | -1238.10000M | -2949.40000M |
| Net borrowings | -1688.00000M | 2063.00M | -1926.00000M | 13343.60M | -442.10000M |
| Total cash from financing activities | -2570.00000M | 1295.00M | 1006.00M | 16365.90M | -797.00000M |
| Change to operating activities | -2.00000M | 135.00M | 247.00M | 452.20M | 131.70M |
| Net income | 7209.00M | 6347.00M | 3646.00M | 2432.30M | 2650.90M |
| Change in cash | 3409.00M | -3449.00000M | -13877.00000M | 19124.50M | 157.70M |
| Begin period cash flow | 2586.00M | 6035.00M | 19912.00M | 787.80M | 630.30M |
| End period cash flow | 5995.00M | 2586.00M | 6035.00M | 19912.30M | 788.00M |
| Total cash from operating activities | 8519.00M | 8358.00M | 6208.00M | 3951.60M | 4022.00M |
| Issuance of capital stock | 31.00M | 86.00M | 3550.00M | 3816.30M | 96.00M |
| Depreciation | 2222.00M | 2168.00M | 1775.00M | 1189.50M | 1307.70M |
| Other cashflows from investing activities | -1082.00000M | 37.00M | -20119.00000M | -361.60000M | -2167.00000M |
| Dividends paid | 818.00M | 742.00M | 615.00M | 750.70M | 433.00M |
| Change to inventory | -486.00000M | -502.00000M | -123.00000M | -21.90000M | -143.30000M |
| Change to account receivables | -477.00000M | -611.00000M | -264.00000M | -156.40000M | -58.30000M |
| Sale purchase of stock | 934.00M | 3249.00M | 5704.00M | 16514.20M | 411.80M |
| Other cashflows from financing activities | -1752.00000M | -16.00000M | -3.00000M | -43.30000M | -364.00000M |
| Change to netincome | -223.00000M | 415.00M | 243.00M | 37.80M | -41.60000M |
| Capital expenditures | 1152.00M | 1294.00M | 791.00M | 635.50M | 584.00M |
| Change receivables | -477.00000M | -611.00000M | -264.00000M | -156.40000M | -58.30000M |
| Cash flows other operating | 7402.00M | 6530.00M | 4205.00M | 2480.00M | 2740.60M |
| Exchange rate changes | - | - | - | 45.10M | -117.70000M |
| Cash and cash equivalents changes | 3715.00M | -3334.00000M | -14025.00000M | 19124.50M | 157.50M |
| Change in working capital | -1519.00000M | -658.00000M | 605.00M | -123.20000M | -90.10000M |
| Stock based compensation | 336.00M | 218.00M | 187.00M | 158.80M | 151.40M |
| Other non cash items | 830.00M | 601.00M | 457.00M | 709.40M | 197.20M |
| Free cash flow | 7367.00M | 7064.00M | 5417.00M | 3316.10M | 3438.00M |
Sector: Healthcare Industry: Diagnostics & Research
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| DHR Danaher Corporation |
0.70 0.35% | 203.20 | 29.09 | 28.01 | 5.67 | 3.20 | 6.00 | 19.09 |
| TMO Thermo Fisher Scientific Inc |
1.57 0.37% | 429.33 | 34.71 | 23.87 | 4.62 | 4.43 | 5.29 | 20.89 |
| A Agilent Technologies Inc |
0.72 0.60% | 121.38 | 34.36 | 26.39 | 6.59 | 7.14 | 6.78 | 23.56 |
| IDXX IDEXX Laboratories Inc |
4.30 0.79% | 547.01 | 49.99 | 45.66 | 11.29 | 27.85 | 11.46 | 34.46 |
| IQV IQVIA Holdings Inc |
-0.41 0.25% | 164.24 | 37.82 | 19.68 | 2.76 | 7.20 | 3.61 | 17.03 |
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, municipal, industrial, and natural resource applications. It also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. The company was founded in 1969 and is headquartered in Washington, the District of Columbia.
2200 Pennsylvania Avenue, NW, Washington, DC, United States, 20037-1701
| Name | Title | Year Born |
|---|---|---|
| Mr. Steven M. Rales | Co-Founder & Chairman | 1951 |
| Mr. Rainer M. Blair | Pres, CEO & Director | 1964 |
| Mr. Mitchell P. Rales | Co-Founder & Director | 1957 |
| Mr. Matthew R. McGrew | CFO & Exec. VP | 1972 |
| Ms. Angela S. Lalor | Part Time Advisor | 1965 |
| Mr. Joakim Weidemanis | Exec. VP | 1969 |
| Ms. Jennifer L. Honeycutt | Exec. VP | 1970 |
| Mr. Christopher M. Bouda | Chief Accounting Officer | NA |
| Dr. Jose-Carlos Gutierrez-Ramos Ph.D. | Sr. VP & Chief Science Officer | 1964 |
| Mr. John Bedford | VP of Investor Relations | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...